Status:
TERMINATED
Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE
Lead Sponsor:
Eli Lilly and Company
Conditions:
Attention Deficit Hyperactivity Disorder
Cannabis Abuse
Eligibility:
All Genders
13-17 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in adolescents with ADHD and comorbid cannabis abuse.
Detailed Description
In the past adolescents with cannabis abuse have been excluded from studies in which atomoxetine for ADHD symptoms was studied. In this study the efficacy of atomoxetine on symptoms of ADHD in adolesc...
Eligibility Criteria
Inclusion
- Diagnosis ADHD based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)
- At least 1.5 standard deviations above the age norm for their diagnostic subtype using published norms for the ADHD Rating Scale-IV-Parent Version
- Cannabis Abuse or dependence based on the DSM-IV-TR, and using a minimum of 5 joints per week
Exclusion
- Weight under 20 kilograms (kg)
- Patients at serious suicidal risk
- Patients with alcohol or drug abuse (other than cannabis)
- Patients who in the investigator's judgement are likely to need psychotropic medication + psychotherapy apart from atomoxetine
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT00687609
Start Date
September 1 2008
End Date
June 1 2009
Last Update
August 24 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
The Hague, Netherlands, 2566 ER